CSG Launches EU Artillery Fuse Production as Q1 Profits Soar – But the Market Remains Cool

The gap between what the Czechoslovak Group is achieving operationally and what its stock price is reflecting has rarely been wider. The defence and ammunition conglomerate posted a 83% surge in first-quarter net profit, signed a binding order for a new electronic fuse joint venture, and expanded contracts with both the US Army and the FBI. Yet its shares have shed 3.34% in the past week and sit roughly 44% below the average analyst price target, with a P/E of 16 versus the European defence sector’s 23.

At the heart of the strategic push is Fuchs Electronics Europe, a 51/49 joint venture with South Africa’s Reunert. The Slovak-based company will manufacture programmable electronic fuses for large-calibre ammunition at CSG’s existing site in Dubnica nad Váhom. Reunert’s Fuchs Electronics subsidiary, which has more than 60 years of fuse design experience, provides the technology. These fuses are standard for NATO 155mm artillery and offer selectable detonation modes – impact, delay, time – that mechanical predecessors cannot match. The joint venture starts with a binding initial order that covers a three-year ramp-up period, after which it is expected to operate independently. Regulatory approvals, including investment screening and competition clearance, are still awaited.

The fuse project strengthens CSG’s vertical integration. But the market’s muted reaction – the weekly loss persisted after the 22 May announcement – suggests investors are looking past the long-term gains and focusing on a short-term headache: the Ammo+ division. That unit saw revenue slide 20.5% year-on-year to €291m in Q1, and operating profit plunged 68.5% to €13m. The culprit was a difficult US market environment following the late-2024 acquisition of Vista Outdoor’s Kinetic Group. Demand has picked up markedly since the end of the first quarter, however, and CSG expects higher prices and increasing capacity to rebuild margins as 2026 progresses.

Quarter one as a publicly listed group was otherwise robust. Revenue climbed 13.8% to €1.544bn, and the Defence Systems segment grew 26.5% to €1.251bn. The order book swelled to €17bn, with a further €27bn in the negotiation pipeline – a level of visibility that gives management unusual planning certainty. Net debt stood at a comfortable 1.3 times operating EBITDA. Net profit hit €299m, lifting the margin from 12% to 19%.

Should investors sell immediately? Or is it worth buying CSG?

The US government business is also expanding. CSG is executing a $635m contract to plan, build and commission the future artillery complex in Iowa, where the ground-breaking is scheduled for this summer. In law enforcement, the company has extended its supply relationship with the FBI and is ramping up production of 5.56mm ammunition for federal agencies and the armed forces.

Analyst opinion remains largely constructive but has turned cautious in tone. On 26 May, Deutsche Bank lowered its price target. Jefferies maintained a buy rating, and Oddo BHF upgraded to “outperform” but at a reduced target. The consensus among ten analysts still points to a buy, with an average target of €32.45 – more than 44% above Friday’s close of €18.08. The 52-week high of €33.81 is now 46.5% away, while the low of €15.73 sits 15% below current levels.

On the technical side, the stock is trading 13% under its 50-day moving average of €20.86, and the 200-day line at €26.19 looks distant. The relative strength index at 60.9 indicates mild cooling rather than overselling. Support is seen around €15.66 and resistance at €25.62. With an annualised 30-day volatility above 77%, CSG remains a high-beta name that can swing sharply on any fresh catalyst.

CSG at a turning point? This analysis reveals what investors need to know now.

The half-year results due on 7 August will be the next major test. If CSG can confirm that the Ammo+ recovery is gaining traction and that the defence order pipeline continues to convert, the discount to peers may finally start to close. For now, the market is demanding proof – and the share price is reflecting patience, not euphoria.

Ad

CSG Stock: New Analysis - 30 May

Fresh CSG information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated CSG analysis...

en | NL0015073TS8 | CSG | boerse | 69448684 |